WallStreetZenWallStreetZen

NASDAQ: CAPR
Capricor Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Capricor Therapeutics revenue was $22.27M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $11.1M, up 392.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CAPR annual revenue was $22.3M, with -11.5% growth year-over-year.

CAPR past revenue growth

How has CAPR's revenue growth performed historically?

Company
-11.55%
Industry
511.06%
Market
20.87%
CAPR's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CAPR's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CAPR's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CAPR revenue history

Current Revenue
$22.3M
Current Earnings
-$40.5M
Current Profit Margin
-181.7%

Be the first to know when CAPR announces revenue.

CAPR Revenue History By Year

CAPR Yearly RevenueCAPR RevenueCAPR ChangeCAPR Revenue Growth
2024-12-31$22.27M-$2.91M-11.55%
2023-12-31$25.18M$22.63M+886.81%
2022-12-31$2.55M$2.31M+941.85%
2021-12-31$244.90k-$65.35k-21.06%
2020-12-31$310.25k-$694.78k-69.13%
2019-12-31$1.01M-$666.33k-39.87%
2018-12-31$1.67M-$994.98k-37.32%
2017-12-31$2.67M-$1.33M-33.32%
2016-12-31$4.00M-$1.52M-27.53%
2015-12-31$5.52M$730.95k+15.27%
2014-12-31$4.79M$4.28M+851.19%
2013-12-31$503.23k-$1.40M-73.50%
2012-12-31$1.90M$544.26k+40.18%
2011-12-31$1.35MN/AN/A
2010-12-31$0.00N/AN/A
2009-12-31$0.00N/AN/A
2008-12-31$0.00-$101.40k-100.00%
2007-12-31$101.40k-$279.44k-73.37%
2006-12-31$380.84kN/AN/A

1 of 2

Capricor Therapeutics Revenue FAQ

What was CAPR's revenue last quarter?

On Invalid Date, Capricor Therapeutics (NASDAQ: CAPR) reported Q4 2024 revenue of $11.13 million up 7.92% year over year. In the same quarter last year, Capricor Therapeutics's revenue was $12.09 million.

What was Capricor Therapeutics's revenue in 2024?

Capricor Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $22.27 million, a 11.55% decrease year over year.

How much does Capricor Therapeutics make in a day?

Based on Capricor Therapeutics annual revenue for the past five years, CAPR makes an average of $27,701.45 per day.

What was Capricor Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Capricor Therapeutics's revenue has grown -11.55% year over year. This is 522.61 percentage points lower than the US Biotechnology industry revenue growth rate of 511.06%. Capricor Therapeutics's revenue in the past year totaled $22.27 million.

How much does Capricor Therapeutics make in a year?

Capricor Therapeutics's revenue by year for the past five years is:
  • Capricor Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $22.27 million, a 11.55% decrease year over year.
  • Capricor Therapeutics's annual revenue for Dec 31, 2023 was $25.18 million, a 886.81% increase from 2022.
  • Capricor Therapeutics's annual revenue for 2022 was $2.55 million, a 941.85% increase from 2021.
  • Capricor Therapeutics's annual revenue for 2021 was $244.90 thousand, a 21.06% decrease from 2020.
  • Capricor Therapeutics's annual revenue for 2020 was $310.25 thousand, a 69.13% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.